Epidemiology, comorbidities at diagnosis and outcomes associated with HIV late diagnosis from 2010 to 2019 in a Belgian reference centre: A retrospective study.
AIDS
HIV
comorbidities
late diagnosis
outcomes
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
01
07
2022
accepted:
20
10
2022
pubmed:
11
11
2022
medline:
3
12
2022
entrez:
10
11
2022
Statut:
ppublish
Résumé
Our objective was to investigate the demographic factors, comorbidities, and outcomes of patients with a late diagnosis (LD) of HIV in a Belgian HIV reference centre. All patients with HIV who presented for care between 2010 and 2019 were included. They were excluded if time between diagnosis and presentation or first CD4 count exceeded 6 months or if they had previously received antiretroviral therapy (ART). LD was defined as a CD4 cell count ≤350/mm Of 1078 patients, 427 (39.6%) were LD. In multivariable analysis, the following factors were associated with LD: non-homosexual transmission route, being born in Sub-Saharan Africa (SSA), and age ≥35 years. Prevalence at diagnosis of malignancies, diabetes, and cardiovascular diseases did not differ between non-LD and LD, whereas renal impairment was more frequent in LD. In univariable analysis, high-density lipoprotein (HDL) cholesterol <40 mg/dL and estimated glomerular filtration rate <60 ml/min were associated with LD; in multivariable analysis, only HDL cholesterol <40 mg/dL was associated. Patients with LD experienced more adverse events leading to a switch in ART, virological failure, and death during follow-up. LD remains common in our centre, especially in non-homosexual patients and those born in SSA. Although not associated with an important burden of comorbidities at diagnosis, it still results in poorer outcomes, emphasizing the need to expand coverage and access to HIV testing.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1184-1194Informations de copyright
© 2022 British HIV Association.
Références
The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
Antinori A, Coenen T, Costagiola D, et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2011;12(1):61-64.
Mocroft A, Lundgren JD, Sabin ML, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the collaboration of observational HIV epidemiological research Europe study (COHERE). PLoS Med. 2013;10(9):e1001510.
Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). Aids. 2006;20(18):2371-2379.
Montlahuc C, Guiguet M, Abgrall S, et al. Impact of late presentation on the risk of death among HIV-infected people in France (2003-2009). J Acquir Immune Defic Syndr. 2013 Oct;64(2):197-203.
Waters L, Fisher M, Anderson J, et al. Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters. HIV Med. 2011;12(5):289-298.
Rava M, Bisbal O, Domínguez-Domínguez L, et al. Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment. Aids. 2021;35(8):1283-1293.
Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr. 2007;46(4):456-462.
Late Presentation Working Groups in EuroSIDA and COHERE. Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010-2016. BMC Infect Dis. 2020;20(1):728.
Krentz HB, Gill MJ. The direct medical costs of late presentation (<350/mm) of HIV infection over a 15-year period. AIDS Res Treat. 2012;2012:757135.
Deblonde J, De Rouck M, Montourcy M, Serrien B, Van Beckhoven D. Epidémiologie du SIDA et de l'infection à VIH en Belgique. Situation au 31 décembre 2020.
European Centre for Disease Prevention and Control., World Health Organization. HIV/AIDS surveillance in Europe 2021: 2020 data.
Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive PARTNER taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. The Lancet. 2019;393(10189):2428-2438.
Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. Aids. 2006;20(10):1447-1450.
Gesesew HA, Tesfay Gebremedhin A, Demissie TD, Kerie MW, Sudhakar M, Mwanri L. Significant association between perceived HIV related stigma and late presentation for HIV/AIDS care in low and middle-income countries: a systematic review and meta-analysis. PLoS ONE. 2017 Mar 30;12(3):e0173928.
Burns FM, Johnson AM, Nazroo J, et al. Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK. Aids. 2008 Jan 2;22(1):115-122.
Hachfeld A, Ledergerber B, Darling K, et al. Reasons for late presentation to HIV care in Switzerland. J Int AIDS Soc. 2015;18:20317.
Tavoschi L, Dias JG, Pharris A, et al. New HIV diagnoses among adults aged 50 years or older in 31 European countries, 2004-15: an analysis of surveillance data. Lancet HIV. 2017 Nov 1;4(11):e514-e521.
Tominski D, Katchanov J, Driesch D, et al. The late-presenting HIV-infected patient 30 years after the introduction of HIV testing: spectrum of opportunistic diseases and missed opportunities for early diagnosis. HIV Med. 2017 Feb;18(2):125-132.
Ransome Y, Terzian A, Addison D, et al. Expanded HIV testing coverage is associated with decreases in late HIV diagnoses, new York City, 2003 to 2010. Aids. 2015 Jul 17;29(11):1369-1378.
The late presenters working group in COHERE in EuroCoord. Late presentation for HIV care across Europe: update from the collaboration of observational HIV epidemiological research Europe (COHERE) study, 2010 to 2013. Euro Surveill. 2015 Nov 26;20(47):30070 20.
The socio-economic inequalities and HIV writing Group for Collaboration of observational HIV epidemiological research in Europe (COHERE) in EuroCoord. Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. Aids. 2014 Sep 24;28(15):2297-2306.
Yombi JC, Jonckheere S, Vincent A, Wilmes D, Vandercam B, Belkhir L. Late presentation for human immunodeficiency virus HIV diagnosis results of a Belgian single centre. Acta Clin Belg. 2014;69(1):33-39.
Darcis G, Lambert I, Sauvage A-S, et al. Factors associated with late presentation for HIV care in a single Belgian reference center: 2006-2017. Sci Rep. 2018;8(1):8594.
Op de Coul ELM, van Sighem A, Brinkman K, et al. Factors associated with presenting late or with advanced HIV disease in The Netherlands, 1996-2014: results from a national observational cohort. BMJ Open. 2016 Jan 4;6(1):e009688.
Jabłonowska E, Szetela B, Bielecki M, et al. Acquired immune deficiency syndrome (AIDS) and late presentation in Poland - data from test and keep in care (TAK) Polska project. HIV Med. 2021 May;22(5):387-396.
Lanoy E, Mary-Krause M, Tattevin P, et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther. 2007;12(1):89-96.
Riddler SA, Smit E, Cole SR, et al. Impact of HIV Infection and HAART on Serum Lipids in Men. JAMA. 2003;289(22):2978.
Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327(5):329-337.
The RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. Aids. 2021 May 1;35(6):869-882.
Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD Study. AIDS. 2003 May 23;17(8):1179-1193.
Ronit A, Sharma S, Baker JV, et al. Serum albumin as a prognostic marker for serious non-AIDS endpoints in the strategic timing of antiretroviral treatment (START) study. J Infect Dis. 2018 Jan 17;217(3):405-412.
Ryom L, Lundgren JD, Reiss P, et al. The impact of immunosuppression on chronic kidney disease in people living with human immunodeficiency virus: the D:a:D study. J Infect Dis. 2021 Feb 15;223(4):632-637.
Ryom L, Lundgren JD, Law M, et al. Serious clinical events in HIV-positive persons with chronic kidney disease. Aids. 2019 Nov 15;33(14):2173-2188.
Achhra AC, Mocroft A, Ross M, et al. Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. Int J Antimicrob Agents. 2017 Sept;50(3):453-460.
Mocroft A, Lundgren JD, Ross M, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016 Jan;3(1):e23-e32.
Guaraldi G, Zona S, Menozzi M, et al. Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study. AIDS Res Ther. 2017 Feb 16;14(1):8.
Hernández-Ramírez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017 Nov;4(11):e495-e504.
Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012 Sep;13(8):453-468.
Schuettfort G, Cabello A, Cotter AG, et al. Reasons for choice of antiretroviral regimens in HIV patients presenting late for initial treatment in Europe. AIDS Patient Care STDS. 2021 Apr;35(4):110-115.
Schuettfort G, Boekenkamp L, Cabello A, et al. Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors. HIV Med. 2021 Jan;22(1):47-53.
Dutertre M, Cuzin L, Demonchy E, et al. Initiation of antiretroviral therapy containing integrase inhibitors increases the risk of IRIS requiring hospitalization. J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e23-e26.
Sasse A, Florence E, Pharris A, et al. Late presentation to HIV testing is overestimated when based on the consensus definition. HIV Med. 2016;17(3):231-234.